The Rhythm | Issue 28
Issue 28 | Week of 12 October 2026
The Heart Failure Society of America (HFSA) Annual Scientific Meeting ran in Phoenix from 9 to 12 October. This week's five papers are new journal publications, two of them reporting trials first presented at congresses earlier in the year.
Cardiology Intelligence Briefing: when the numbers tell only part of the story
Intensive blood pressure treatment can worsen a kidney function measurement without increasing observed kidney failure. That contradiction leads this week's research and raises a broader question: when does a measurable treatment effect translate into a meaningful clinical outcome?1
The clearest answer comes from a meta-analysis of 27 randomised trials involving 88,830 participants. Intensive blood pressure lowering reduced cardiovascular events without a statistically significant increase in kidney failure, despite more sustained declines in estimated glomerular filtration rate (eGFR).1 For clinicians managing chronic kidney disease, a fall in eGFR after treatment intensification warrants assessment, but does not necessarily justify withdrawing therapy that reduces cardiovascular risk.1
Elsewhere, the link between physiological improvement and clinical benefit remains unresolved. Conduction system pacing was non-inferior to biventricular pacing for six-month ejection fraction improvement after atrioventricular node ablation, with shorter procedures, but whether that translates into better long-term outcomes is unknown.2 A repurposed hypoxia-signalling drug failed to reduce infarct size after primary percutaneous coronary intervention (PCI), and its favourable remodelling signals emerged only in secondary analyses unadjusted for multiple comparisons.3
Two further studies show the limits of their designs. In adults with congenital heart disease, coronary disease, sleep apnoea, smoking and depression were independently associated with mortality, but association cannot establish whether targeting these factors improves survival.4 In femoropopliteal disease, a secondary analysis found fewer repeat revascularisations with sirolimus-coated balloons, but its descriptive design and clinician-dependent endpoint cannot establish comparative benefit.5
The implications are not equal. The blood pressure evidence strengthens an existing strategy in appropriately selected patients.1 The pacing trial supports a procedural alternative, while the infarct-size trial provides no basis for a new treatment after ST-segment elevation myocardial infarction (STEMI).2,3 The observational and secondary analyses raise questions without settling treatment decisions.4,5
Evidence must be judged by what it establishes, not by what it measures.
